Celltrion Maintains 70% Combined Market Share for Remsima in Europe... Growth Continues Across New and Existing Product Lines

Omliclo and Aptosma See Rapid Uptake from Early Launch

Tender Volumes to Concentrate in Second Half... "Full Effort to Exceed Performance Targets"

Celltrion announced on May 14 that it continues to see growth in prescriptions for its entire product lineup in the European pharmaceutical market. In addition to the stable prescription trend of its existing products, particularly the Remsima portfolio (IV and SC), newly launched high-profit products are successfully establishing themselves in the market, raising expectations for the company's performance growth this year.

According to IQVIA, a pharmaceutical market research agency, Celltrion's flagship autoimmune disease treatment Remsima portfolio recorded a combined market share of 70% in Europe as of the fourth quarter of last year. The company explained that this steady prescription trend has allowed it to maintain its leadership in the European infliximab market.

Outstanding performance was seen in the five major European countries (EU5). In the United Kingdom, the Remsima portfolio achieved an 83% market share, while in France and Italy, shares stood at 82% and 80%, respectively.

Growth of Remsima SC was also confirmed. In Germany, its market share surpassed the halfway mark at 50%, and in France, it reached 36%. In Greece and Luxembourg, the market share approached nearly 100%.

This performance is attributed to the distinct effect of dual formulation, where patients switch from competing products to Remsima and then transition to Remsima SC. The company stated that, as the only manufacturer worldwide with an infliximab SC formulation, it expects growth momentum based on the synergy within the Remsima portfolio to continue.

Oncology drugs also showed stable prescription trends. The metastatic colorectal cancer and breast cancer treatment Vegzelma (ingredient: bevacizumab) maintained its leading position in the bevacizumab market with a 30% share, up 4% from the previous quarter.

High-profit new products, which have been actively launched in the European market since last year, also showed growth. Omliclo (ingredient: omalizumab), a chronic spontaneous urticaria treatment launched in Europe as a first-mover in September last year, achieved a 15% market share within just two quarters. In Denmark, it secured a 98% market share through a national tender, and prescriptions expanded in other key countries such as Spain (80%) and the Netherlands (70%).

Another autoimmune disease treatment, Aptosma (ingredient: tocilizumab), sequentially launched in major European countries from late last year to January this year, recorded a 5% market share in Europe during the same period. In some countries, including Portugal (30%) and Spain (13%), it posted double-digit market shares.

In the first quarter of this year, Celltrion recorded sales of 1.145 trillion won and operating profit of 321.9 billion won, representing increases of 36% and 115.5%, respectively, compared to the same period last year. The company expects performance growth to accelerate in the second half of the year, as major European tenders are usually concentrated in the second and third quarters, with initial supply also taking place after those periods.

A Celltrion representative stated, "In addition to the stable sales of our core products centered on the Remsima portfolio, our high-profit new products have also shown strong prescription trends from the early stages of their launch in Europe, resulting in achievements across our entire portfolio. We will make every effort to exceed the performance targets we set for this year."

This content was produced with the assistance of AI translation services.